Boulder, CO-based Nivalis Therapeutics rode the hot market for biotech IPOs to a $77 million windfall, banking on a very early-stage cystic fibrosis effort that's looking to ride on the coattails of a new combo therapy from Vertex.
Microbiome pioneer Seres Therapeutics is taking its promising lead therapy and the high expectations for an emerging field in biotech and heading to Wall Street, where it hopes to raise $100 million in an IPO that is likely to provide another litmus test of investors' appetite for new drug technologies.
Death and taxes may both be unavoidable, but Kite Pharma CEO Arie Belldegrun at least knows how to limit the pain on part of that equation.
Adaptimmune Therapeutics has become one of the brightest hopes in the U.K. biotech scene, scoring a $350 million collaboration pact with GlaxoSmithKline and a whopping $104 million venture round. Now Adaptimmune--a 2014 Fierce 15 company--will see if it can keep the hot streak rolling with a $150 million IPO pitch.
Biotech VC stalwart Flagship Ventures put together a $537 million new fund, its largest ever, with eyes on a new generation of life sciences upstarts.
The U.K.'s Summit Therapeutics is elbowing its way into the race to treat Duchenne muscular dystrophy, pulling off a $34 million U.S. IPO to fund its research.
Cerenis Therapeutics has filed the paperwork for an IPO in Europe as it looks to bounce back from the failure of a Phase II trial of its HDL-like drug.
Former Elan CEO Kelly Martin and other people with links to the Irish drugmaker are aiming to raise up to €325 million ($364 million) in an IPO to bankroll their life science investment fund. The IPO on the Irish Stock Exchange could dwarf last year's listing by Circassia and become one of the biggest floats in European biotech history.
PARIS-- Paris-based Cellectis has followed through with plans for an IPO in the U.S., filing Friday to raise $115 million in the hot American market as it pushes ahead on CAR-T research.
CRO conglomerate PRA Health Sciences pulled off a $306 million IPO, joining the growing list of Big Pharma contractors cashing in on Wall Street after years under private equity stewardship.